Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam is well-positioned for success with its strong cash position of $12.4 million following a recent successful public offering, and its ongoing pilot study for heart attack detection, which could significantly expand the company's market potential. Additionally, the company's technology platform and business model show potential for high recurring margins and relatively rapid payback on customer acquisition costs. Potential risks include failure in clinical trials, competition, dilution, and going concern. However, with a large and expanding market opportunity for cardiovascular disease detection and management, paired with the incorporation of AI-driven intelligence, HeartBeam has the potential to become a major player in the medical technology industry.

Bears say

HeartBeam is a medical technology company that has received FDA clearance for its higher resolution ambulatory ECG solutions. Despite this, the company's limited market release and onboarding phase suggest a slow sales ramp-up, with meaningful revenue not expected until 2H26. The company's recent equity offering has strengthened their balance sheet, but dilution risk and the need for additional capital for commercialization and clinical development may impact future financials. The company's proprietary and patented technology may provide a competitive advantage, but competition and challenges to existing patents could weaken their positioning. Market development, reimbursement, and technology and product performance risks also pose potential challenges for the company's success.

HeartBeam (BEAT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.